OBJECTIVE: To probe into the effects of doxofylline combined with pidotimod on oxidative stress response in patients with obstructive sleep apnea hypopnea syndrome（OSAHS）. METHODS: Totally 130 patients with OSAHS in Handan Central Hospital in 2020 were divided into control group and research group by random number table method

with 65 cases in each group. Both groups were given conventional therapy

the control group was treated with doxofylline

the research group was treated with pidotimod based on the control group. The clinical efficacy and adverse drug reactions of the two groups were evaluated. The degree of daytime sleepiness

the longest duration of sleep breathing disorder

sleep apnea hypopnea index（AHI）

mean oxyhemoglobin saturation（MSaO

2

）

minimum oxyhemoglobin saturation（LSaO

2

）

malondialdehyde（MDA） and serum superoxide dismutase（SOD） levels before and after treatment were compared between two groups. RESULTS: The total effective rate of research group（96.92%

63/65） was significantly higher than that of the control group（89.23%

58/65）

with statistically significant difference（P

<

0.05）. After treatment

improvement of the degree of daytime sleepiness was significantly better in the research group than the control group

with statistically significant difference（P

<

0.05）. After treatment

the longest duration of sleep breathing disorder of both groups were significantly shorter than before treatment

the AHI and MDA levels were significantly lower than before treatment

the SOD

LSaO

2

and MSaO

2

levels were significantly higher than before treatment

and the above indicators were significantly better in research group than in the control group

with statistically significant differences（P

<

0.05）. The incidences of adverse drug reactions of research group and control group were respectively 4.62%（3/65） and 1.54%（1/65）

the difference was not statistically significant（P

>

0.05）. CONCLUSIONS: The efficacy and safety of doxofylline combined with pidotimod in the treatment of OSAHS is remarkable

which can not only improve oxidative stress response and oxyhemoglobin saturation of patients

but also improve sleep breathing disorder.